Premium
New Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation
Author(s) -
VILESGONZALEZ JUAN F.,
FUSTER VALENTIN,
HALPERIN JONATHAN L.
Publication year - 2011
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1111/j.1540-8167.2011.02104.x
Subject(s) - medicine , edoxaban , rivaroxaban , dabigatran , apixaban , atrial fibrillation , antithrombotic , stroke (engine) , discovery and development of direct thrombin inhibitors , intensive care medicine , cardiology , anticoagulant , warfarin , thrombin , mechanical engineering , platelet , engineering
New Anticoagulants in Atrial Fibrillation . Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for ischemic stroke. Antithrombotic therapy using vitamin K antagonists (VKA) is currently prescribed for prevention of ischemic stroke in patients with AF. A narrow therapeutic range and frequent food and drug interactions underly the need for regular monitoring of anticoagulation intensity and impairs the utility and safety of VKA, stimulating a quest for alternative anticoagulant agents. Recently developed anticoagulants include the direct thrombin inhibitor, dabigatran, and the factor Xa inhibitors rivaroxaban, apixaban, edoxaban, to name those in the most advanced stages of clinical development. This review focuses on advances in the development of novel antithrombotic agents to provide practical information to clinicians on the use of these new drugs in patients with AF. (J Cardiovasc Electrophysiol, Vol. 22, pp. 948‐955, August 2011)